Compare Akamai Technologies, Inc. (AKAM) vs Biogen Inc (BIIB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Akamai Technologies, Inc. vs Biogen Inc — how do they compare? Akamai Technologies, Inc. trades at $123.93 (market cap $16.63B), while Biogen Inc trades at $203.73 (market cap $30.37B). The key difference: Biogen Inc is the larger of the two by market cap, and Biogen Inc is trading nearer its 52-week high, Akamai Technologies, Inc. nearer its low. Which is the better fit depends on your goals.
| AKAM | BIIB | |
|---|---|---|
Market Cap | $16.63B | $30.37B |
Sector | Technology | Health |
52-Week High | $161.14 | $216.63 |
52-Week Low | $70.53 | $122.68 |
Enterprise Value | $21.56B | $32.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Akamai Technologies (AKAM) trades at $114.37, up 1.06% on the day but down significantly from its 26-year high of $165.45 in May 2026. The stock faces a bearish technical signal despite recent earnings beats. Revenue growth has slowed to 5% annually, with net income margin declining from 14.47% in 2022 to 10.74% in 2025. The company continues strategic moves in cybersecurity, completing the LayerX acquisition and expanding its NVIDIA partnership for AI security.
While analyst consensus remains positive with a $170.20 price target, near-term headwinds include declining profitability, high valuation multiples, and competitive pressures. The stock's current pullback presents a potential entry point for long-term investors believing in its cybersecurity and cloud computing positioning, though execution risks and margin compression require monitoring.
Biogen (BIIB) trades at $205.70, down 4.82% today, with a bullish technical signal and strong earnings beat history. The stock shows solid fundamentals with a P/E of 22.42, net income margin of 13.81%, and positive cash flow trends. Recent acquisitions like RayThera for up to $1 billion aim to expand its immunology pipeline, while Alzheimer's portfolio updates at AAIC 2026 provide near-term catalysts. Analyst consensus is bullish with a $224.82 price target, though legal investigations and legacy drug sales declines pose headwinds.
The outlook remains positive given earnings momentum and strategic pipeline investments, but investors face risks from ongoing legal probes and competitive pressures. The stock offers upside to consensus targets if new drug launches offset revenue declines, but volatility may persist amid sector rotation and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
